AR038298A1 - Sales estables del acido o-acetilsalicilico con aminoacidos basicos i i - Google Patents

Sales estables del acido o-acetilsalicilico con aminoacidos basicos i i

Info

Publication number
AR038298A1
AR038298A1 ARP030100121A ARP030100121A AR038298A1 AR 038298 A1 AR038298 A1 AR 038298A1 AR P030100121 A ARP030100121 A AR P030100121A AR P030100121 A ARP030100121 A AR P030100121A AR 038298 A1 AR038298 A1 AR 038298A1
Authority
AR
Argentina
Prior art keywords
basic amino
amino acids
stable salts
grain size
medicines
Prior art date
Application number
ARP030100121A
Other languages
English (en)
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of AR038298A1 publication Critical patent/AR038298A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)

Abstract

Composiciones mejoradas con sales estables del ácido o-acetilsalicílico con aminoácidos básicos, a medicamentos que las contienen así como a su uso para la fabricación de medicamentos. Reivindicación 1: Composición que comprende una sal del ácido o-acetilsalicílico con un aminoácido básico que presenta en una distribución de tamanos de grano medida en condiciones estándar con un aparato Malvern 2600D un tamano medio de grano superior a un tamano de grano de 160 micrones y una proporción de más del 60% de las partículas con un tamano de grano en un intervalo de 100 a 200 micrones, caracterizada porque la composición comprende adicionalmente un agente de fluencia y/o está granulada.
ARP030100121A 2002-01-18 2003-01-16 Sales estables del acido o-acetilsalicilico con aminoacidos basicos i i AR038298A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10202019A DE10202019A1 (de) 2002-01-18 2002-01-18 Stabile Salze von o-Acetylsalicylsäure mit basischen Aminosäuren II

Publications (1)

Publication Number Publication Date
AR038298A1 true AR038298A1 (es) 2005-01-12

Family

ID=7712593

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100121A AR038298A1 (es) 2002-01-18 2003-01-16 Sales estables del acido o-acetilsalicilico con aminoacidos basicos i i

Country Status (31)

Country Link
US (1) US20050171070A1 (es)
EP (1) EP1469835B1 (es)
JP (1) JP2005519892A (es)
KR (1) KR20040079936A (es)
CN (1) CN1298314C (es)
AR (1) AR038298A1 (es)
AT (1) ATE378040T1 (es)
AU (1) AU2003235700B2 (es)
BR (1) BR0307009A (es)
CA (1) CA2473893A1 (es)
CO (1) CO5611102A2 (es)
CU (1) CU20040161A7 (es)
DE (2) DE10202019A1 (es)
EC (1) ECSP045192A (es)
ES (1) ES2297166T3 (es)
GT (1) GT200300004A (es)
HK (1) HK1080371A1 (es)
HN (1) HN2003000015A (es)
HR (1) HRP20040742B1 (es)
IL (1) IL162881A0 (es)
MX (1) MXPA04006832A (es)
NO (1) NO20043404L (es)
NZ (1) NZ534128A (es)
PE (1) PE20030731A1 (es)
PL (1) PL370197A1 (es)
RS (1) RS63804A (es)
SV (1) SV2004001457A (es)
TW (1) TWI265810B (es)
UY (1) UY27612A1 (es)
WO (1) WO2003059323A2 (es)
ZA (1) ZA200405533B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004025535A1 (de) * 2004-05-25 2005-12-22 Bayer Healthcare Ag Kombination von Salzen der o-Acetylsalicylsäure und Alpha-Glucosidase-Inhibitoren
DE102005025283A1 (de) * 2005-06-02 2006-12-07 Bayer Healthcare Ag Stabiler Wirkstoffkomplex von Salzen der o-Acetylsalicylsäure mit basischen Aminosäuren und Glycin
DE102005049293A1 (de) * 2005-10-15 2007-04-26 Bayer Healthcare Ag Kombinationspräparate von Salzen oder o-Acetylsalicylsäure
DE102008004386A1 (de) * 2008-01-14 2009-07-23 Activaero Gmbh Verwendung eines Acetylsalicylsäuresalzes zur Behandlung viraler Infektionen
JP5309977B2 (ja) * 2008-12-26 2013-10-09 ライオン株式会社 チュアブル錠
US8173625B2 (en) * 2009-05-08 2012-05-08 Theaprin Pharmaceuticals Inc. Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine
CN102803199B (zh) * 2009-06-25 2015-04-15 泰特拉有限公司 乙酰水杨酸盐
JP5563835B2 (ja) * 2010-01-15 2014-07-30 全星薬品工業株式会社 アスピリン錠剤の製造方法
ITMI20121144A1 (it) * 2012-06-28 2013-12-29 Dipharma Francis Srl Procedimento per la preparazione di un sale di un farmaco antinfiammatorio non steroideo
PT3558920T (pt) * 2016-12-23 2021-06-09 Aspiair Gmbh Síntese melhorada de partículas de acetilsalicilato de lisina · glicina
RU2738831C1 (ru) * 2020-03-03 2020-12-17 федеральное государственное бюджетное образовательное учреждение высшего образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РостГМУ Минздрава России) Способ консервативного лечения невралгии тройничного нерва

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5610110A (en) * 1979-07-06 1981-02-02 Green Cross Corp:The Acetyl salicylate salt preparation for injection
FR2611501B1 (fr) * 1987-03-04 1991-12-06 Corbiere Jerome Nouvelles compositions pharmaceutiques pour la voie buccale a base d'acetylsalielylate de lysine et leur procede d'obtention
DE10034802A1 (de) * 2000-07-18 2002-01-31 Bayer Ag Stabile Salze von O-Acetylsalicylsäure mit basischen Aminosäuren

Also Published As

Publication number Publication date
CU20040161A7 (es) 2007-03-23
NO20043404L (no) 2004-08-16
ATE378040T1 (de) 2007-11-15
EP1469835B1 (de) 2007-11-14
PL370197A1 (en) 2005-05-16
EP1469835A2 (de) 2004-10-27
ES2297166T3 (es) 2008-05-01
DE50308596D1 (de) 2007-12-27
HRP20040742A2 (en) 2005-08-31
SV2004001457A (es) 2004-05-07
NZ534128A (en) 2005-08-26
HRP20040742B1 (en) 2008-05-31
CN1298314C (zh) 2007-02-07
US20050171070A1 (en) 2005-08-04
ZA200405533B (en) 2005-07-13
JP2005519892A (ja) 2005-07-07
HN2003000015A (es) 2003-08-22
BR0307009A (pt) 2004-11-03
WO2003059323A3 (de) 2004-03-11
AU2003235700B2 (en) 2007-06-28
CN1642528A (zh) 2005-07-20
KR20040079936A (ko) 2004-09-16
GT200300004A (es) 2003-08-22
CO5611102A2 (es) 2006-02-28
IL162881A0 (en) 2005-11-20
UY27612A1 (es) 2003-08-29
WO2003059323A2 (de) 2003-07-24
PE20030731A1 (es) 2003-09-22
HK1080371A1 (en) 2006-04-28
RS63804A (en) 2006-12-15
TW200306199A (en) 2003-11-16
CA2473893A1 (en) 2003-07-24
TWI265810B (en) 2006-11-11
ECSP045192A (es) 2004-08-27
DE10202019A1 (de) 2003-07-24
AU2003235700A1 (en) 2003-07-30
MXPA04006832A (es) 2004-12-06

Similar Documents

Publication Publication Date Title
AR030305A1 (es) Composicion que comprende sales de acido o-acetilsalicilico con aminoacidos basicos, un procedimiento para su preparacion, uso de dicha composicion para la manufactura de un medicamento
AR038298A1 (es) Sales estables del acido o-acetilsalicilico con aminoacidos basicos i i
CO6331421A2 (es) Gel de quitosano para aplicaciones dermatologicas proceso de obtencion y uso del mismo
BRPI0516100A (pt) clorotalonil moìdo a submicron, e usos do mesmo
MY151458A (en) Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
Kato et al. Activity of matrix metalloproteinases in bovine versus human dentine
AR038375A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
RS51764B (en) TRANSDERMAL PHARMACEUTICAL COMPOSITION
AR018704A1 (es) Parche con efecto de campo magnetico
PT93730A (pt) Processo para a preparacao de composicoes de produto de consumo solido que contem complexos de ciclodextrina com particulas pequenas
BR9914932A (pt) Processo para a manufatura de uma composição de isotretinoìna, composição de isotretinoìna micronizada, forma de dosagem unitária para administração enteral e composição farmacêutica na forma de dosagem unitária
BR112012026223A2 (pt) formulação adequada para o uso em ração animal, uso, e ração para animais.
IT1141482B (it) Sali misti di amminoacidi essenziali o semi-essenziali e loro analoghi non azotati,nonche' loro impiego nella terapia di disfunzioni renali ed epatiche
UY27619A1 (es) Ésteres hidroxamato del ácido n-(4-fenil sustituido)- antranílico
BR0315808A (pt) Composições biocìdicas aquosa e sólida contendo bromo ativo e processo de produção destas
BRPI0413957A (pt) processo para preparar diterpenos solúveis em água, solução aquosa e suas aplicações
ES2155517T3 (es) Derivados del acido n-acetil-neuraminico y procedimientos para su preparacion.
BRPI0416215A (pt) forma de ministração individualmente dosada, não comprimida, processo para produzir uma forma de ministração individualmente dosada, não comprimida e uso de pelo menos um agente de estabilização
LV11818A (lv) Jauna farmaceitiska kompozicija stabilas pulverveida zalu formas pagatavosanai
BR112014027213A8 (pt) nova composição de alfentanil para o tratamento de dor aguda
CN106619211A (zh) 一种晒后修复面膜
NO20033704D0 (no) Fremgangsmåte for fremstilling av D-pantotensyre og/eller salter som tilsetning til dyrefôr
Queiroz et al. Report of two microabrasion techniques of enamel to remove stains and discussion
ES2106689B1 (es) Nueva formulacion a base de acido hidroxicitrico (sales y derivados) y sus aplicaciones cosmeticas y farmaceuticas por via topica percutanea.
MX2023003147A (es) Mezclas de polisorbato que tienen distribucion de esteres de acidos grasos modificados.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal